| David Martin Cassel, MD | |
|
4403 Harrison Blvd, Ogden, UT 84403-3271 | |
| (801) 387-7150 | |
| (801) 387-7155 |
| Full Name | David Martin Cassel |
|---|---|
| Gender | Male |
| Speciality | Medical Oncology |
| Experience | 10 Years |
| Location | 4403 Harrison Blvd, Ogden, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972922938 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 10248657-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mckay Dee Hospital | Ogden, UT | Hospital |
| Layton Hospital | Layton, UT | Hospital |
| Logan Regional Hospital | Logan, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced head and neck cancers.
Elsevier, a world-leading publisher of scientific, technical and medical information products and services, today announced that several universities have purchased its new SciVal Spotlight tool.
Health Minister Pierre Pettigrew today announced that funding for the Canadian Strategy on HIV/AIDS (CSHA) will double over the next five years to $84.4 million annually. In the first year, funding will be targeted to support community-based organizations working with populations most at risk of infection.
WHITEHOUSE STATION known as MSD outside the United States and Canada, and Luminex Corporation have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).
A genetically engineered virus can selectively kill cancerous cells in the lung and colon while leaving healthy cells intact, according to new research published today in Cancer Research by William Wold and colleagues at Saint Louis University School of Medicine.
› Verified 9 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced head and neck cancers.
Elsevier, a world-leading publisher of scientific, technical and medical information products and services, today announced that several universities have purchased its new SciVal Spotlight tool.
Health Minister Pierre Pettigrew today announced that funding for the Canadian Strategy on HIV/AIDS (CSHA) will double over the next five years to $84.4 million annually. In the first year, funding will be targeted to support community-based organizations working with populations most at risk of infection.
WHITEHOUSE STATION known as MSD outside the United States and Canada, and Luminex Corporation have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).
A genetically engineered virus can selectively kill cancerous cells in the lung and colon while leaving healthy cells intact, according to new research published today in Cancer Research by William Wold and colleagues at Saint Louis University School of Medicine.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Martin Cassel, MD 4403 Harrison Blvd, Ogden, UT 84403-3271 Ph: (801) 387-7150 | David Martin Cassel, MD 4403 Harrison Blvd, Ogden, UT 84403-3271 Ph: (801) 387-7150 |
News Archive
Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced head and neck cancers.
Elsevier, a world-leading publisher of scientific, technical and medical information products and services, today announced that several universities have purchased its new SciVal Spotlight tool.
Health Minister Pierre Pettigrew today announced that funding for the Canadian Strategy on HIV/AIDS (CSHA) will double over the next five years to $84.4 million annually. In the first year, funding will be targeted to support community-based organizations working with populations most at risk of infection.
WHITEHOUSE STATION known as MSD outside the United States and Canada, and Luminex Corporation have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).
A genetically engineered virus can selectively kill cancerous cells in the lung and colon while leaving healthy cells intact, according to new research published today in Cancer Research by William Wold and colleagues at Saint Louis University School of Medicine.
› Verified 9 days ago
Ewa Gniado, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4403 Harrison Blvd Ste 3630, Ogden, UT 84403 Phone: 801-387-7900 Fax: 801-387-7910 | |
Jaclyn Nguyen, Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 4403 Harrison Blvd Ste 3630, Ogden, UT 84403 Phone: 801-387-7900 | |
Dr. Timothy Trask, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4401 Harrison Blvd, Ogden, UT 84403 Phone: 801-387-3654 | |
Gregory T Almony, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5405 S 500 E, Suite #204, Ogden, UT 84405 Phone: 801-479-0194 Fax: 801-479-5642 | |
Brian W Pugh, DO Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 6028 S Ridgeline Dr, Ste 201, Ogden, UT 84405 Phone: 801-475-5400 Fax: 801-475-8614 | |
Dr. Jack D Wahlen, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 4403 Harrison Blvd, Ste 3630, Ogden, UT 84403 Phone: 801-387-7900 Fax: 801-387-7910 | |
Gary K Goucher, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 4403 Harrison Blvd, #3815, Ogden, UT 84403 Phone: 801-387-2575 Fax: 801-387-2585 |